Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) Completed Phase 2 Trials for Flu caused by Influenza Prevention

CompletedPrevention2 IdentifierTitleDrugs
NCT02719743A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
NCT02586792H7N9 Boost in Healthy Adults
NCT01746082Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations
NCT01416571Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
NCT00980850Swine Flu (Novel Influenza A H1N1) Vaccine Study
NCT00742885Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
NCT00719043Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00695669A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
NCT00617331H9 Priming Study in Healthy Adults
NCT00240968H5 Booster After a Two Dose Schedule